반응식
[F:1][C:2]1[CH:9]=[CH:8][C:5]([CH:6]=O)=[C:4]([C:10]([F:13])([F:12])[F:11])[CH:3]=1.[NH2:14][C:15]1[CH:16]=[C:17]2[C:21]3=[C:22]([CH2:24][S:25][CH2:26][CH2:27][N:20]3[C@H:19]3[CH2:28][CH2:29][N:30](C(OC(C)(C)C)=O)[CH2:31][C@@H:18]23)[CH:23]=1>>[F:1][C:2]1[CH:9]=[CH:8][C:5]([CH2:6][NH:14][C:15]2[CH:16]=[C:17]3[C:21]4=[C:22]([CH2:24][S:25][CH2:26][CH2:27][N:20]4[C@H:19]4[CH2:28][CH2:29][NH:30][CH2:31][C@@H:18]34)[CH:23]=2)=[C:4]([C:10]([F:13])([F:12])[F:11])[CH:3]=1참가 물질
3
반응물 2
생성물 1
실험 절차
Using 4-fluoro-2-(trifluoromethyl)benzaldehyde and following the procedures described in EXAMPLE 126, tert-butyl (7bR,11aS)-6-amino-1,2,7b,10,11,11a-hexahydro-4H-pyrido[4,3-b][1,4]thiazepino[6,5,4-hi]indole-9(8H)-carboxylate from EXAMPLE 33, Part B was converted into the title compound of EXAMPLE 154. 1H NMR(CDCl3) δ: 9.30 (broad s, 1H), 9.15 (broad s, 1H), 7.60-7.52 (m, 1H), 7.38-7.25 (m, 1H), 7.13 (broad t, 1H, J=8.0 Hz), 6.30-6.15 (broad m, 2H), 4.45-4.25 (broad m, 2H), 4.17-3.98 (broad m, 2H)1 3.70-3.30 (m, 4H), 3.30-2.70 (broad m, 5H), 2.60-2.47 (m, 1H), 2.20-2.00 (m, 2H). LRMS (ES)+: 438.4 (M+H)+.
출처 및 근거
- ORD 기록
- ord-283ee36fdb0849e6b68f6a949acfce4b
- 출처 데이터셋
- uspto-grants-2004_03
- 특허 번호
- US06699852B2
연결된 노트
불러오는 중…